News FocusClinical Trials

Nail-Biting Time for Trials of COX-2 Drugs

Science  03 Dec 2004:
Vol. 306, Issue 5702, pp. 1673-1675
DOI: 10.1126/science.306.5702.1673

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Preliminary studies suggest that the COX-2 inhibitor Celebrex may stem cancer and Alzheimer's disease, but testing these possibilities has just gotten tougher.

Related Content